TrialInflammatory bowel diseases2018

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting.

Siew C Ng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.